

22 July 2022

**Diaceutics PLC**  
**("Diaceutics" or "the Company")**

**PDMR Shareholding/Share Incentive Plan**

[Diaceutics PLC](#), (AIM: DXRX), a leading diagnostic commercialisation company which provides data, analytics and technology enabled services via its DXRX platform to the precision medicine market, has been notified that on 21 July 2022, Global Shares Trustees (UK) Limited and Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, have purchased ordinary shares ("Shares") on behalf of Stefan McDonald and Susanne Munksted (PDMRs), in respect of their purchase of Shares pursuant to the Company's UK and Global Share Incentive Plan ("the SIP Schemes") for employees. These purchases will be made each month until further notice.

In accordance with the SIP Schemes, the Company has matched these purchases with a matched share award over an equivalent number of Shares purchased by the employee, in the proportion of 1:1.

**Enquiries:**

**Diaceutics PLC**

Nick Roberts, Chief Financial Officer

Via Alma PR

**Stifel Nicolaus Europe Limited (Nomad & Broker)**

Tel: +44 (0)20 7710 7600

Ben Maddison  
Stewart Wallace  
Nick Adams

**Alma PR**

Tel: +44(0)20 3405 0205  
diaceutics@almapr.co.uk

Caroline Forde  
Kieran Breheny  
Matthew Young

**About Diaceutics**

At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network®.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.

Diaceutics' data capability is one of the three key value drivers it has integrated into its unique DXRX platform alongside its global Lab network and product suite tailored for Precision testing.

<b>Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</b>		
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>		
a.	Name	Stefan McDonald
<b>2 Reason for notification</b>		
a.	Position/Status	Chief Growth Officer and PDMR
b.	Initial notification/ Amendment	Initial
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a.	Name	Diaceutics PLC

b.	LEI	213800VEWQBB39ZB8J81								
<b>4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>										
a.	Description of the financial instrument, type of instrument  Identification Code	Ordinary shares of £0.002 each  ISIN: GB00BJQTGV64								
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Diaceutics plc UK Share Incentive Plan ("SIP")								
c.	Price(s) and volume(s)	Share purchase: <table border="1" style="margin-left: 40px;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>0.89 p</td> <td>168</td> </tr> </tbody> </table> Matched share award: <table border="1" style="margin-left: 40px;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>0.89 p</td> <td>168</td> </tr> </tbody> </table>	Price(s)	Volume(s)	0.89 p	168	Price(s)	Volume(s)	0.89 p	168
Price(s)	Volume(s)									
0.89 p	168									
Price(s)	Volume(s)									
0.89 p	168									
e.	Date of the transaction	Share purchase and Matched Share award: 21 July 2022								
f.	Place of the transaction	Share Purchase and Matched Share Award: AIM Market of the London Stock Exchange								

<b>Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014</b>						
<b>1 Details of the person discharging managerial responsibilities/person closely associated</b>						
a.	Name	Susanne Munksted				
<b>2 Reason for notification</b>						
a.	Position/Status	Chief Precision Medicine Officer and PDMMR				
b.	Initial notification/ Amendment	Initial				
<b>3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>						
a.	Name	Diaceutics PLC				
b.	LEI	213800VEWQBB39ZB8J81				
<b>4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>						
a.	Description of the financial instrument, type of instrument  Identification Code	Ordinary shares of £0.002 each  ISIN: GB00BJQTGV64				
b.	Nature of the transaction	Ongoing non-discretionary purchase of Shares matched by the grant of conditional share award over Shares under the Global Share Incentive Plan ("SIP")				
c.	Price(s) and volume(s)	Share purchase: <table border="1" style="margin-left: 40px;"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td></td> <td></td> </tr> </tbody> </table>	Price(s)	Volume(s)		
Price(s)	Volume(s)					

		<table border="1"> <tr> <td>0.89 p</td> <td>165</td> </tr> <tr> <td colspan="2">Conditional share award:</td> </tr> <tr> <td>Price(s)</td> <td>Volume(s)</td> </tr> <tr> <td>Nil</td> <td>165</td> </tr> </table>	0.89 p	165	Conditional share award:		Price(s)	Volume(s)	Nil	165
0.89 p	165									
Conditional share award:										
Price(s)	Volume(s)									
Nil	165									
e.	Date of the transaction	Share purchase and Conditional share award: 21 July 2022								
f.	Place of the transaction	Share Purchase: AIM Market of the London Stock Exchange Conditional share award: Off-Market								

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHBKBBQABKDQOB